Patient disposition.^aTwo patients received a maximum dose of 5.5 g sutimlimab in accordance with versions 1 and 2 of the protocol and completed part A only; 1 patient received doses of 5.5 g and 6.5 g, and 2 patients received doses of 5.5 g and 7.5 g. ^bFour patients discontinued part A due to reasons unrelated to sutimlimab; 3 discontinued due to the need for rescue therapy or unresponsiveness as per the investigator’s decision, and 1 discontinued due to reasons unknown. ^cOnly patients with evidence of treatment efficacy in part A were eligible for part B. One durable responder from part A did not enroll in part B because part B was not included in the study protocol at that time. ^dThree patients discontinued due to reasons unrelated to sutimlimab: 2 discontinued due to the need for rescue therapy or unresponsiveness as per the investigator’s decision, and 1 patient chose to withdraw (the participant required rescue therapy for severe thrombocytopenia and then withdrew consent at the early terminated visit).